...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
【24h】

Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.

机译:Flavopiridol是细胞周期蛋白依赖性激酶的抑制剂,可在体内和体外诱导膀胱癌细胞的生长抑制和凋亡。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Flavopiridol is a semi-synthetic flavone analog of the alkaloid, rohitukine, a compound from an Indian tree, Dysoxylum binectariferum. It has been shown to inhibit cyclin-dependent kinases (CDKs), causing cell cycle arrest and growth inhibition. Flavopiridol is reported to have cytotoxic activity against a wide range of cancer cell lines and has demonstrated its efficacy in several clinical trials. Flavopiridol seems a well-suited potential new agent for the treatment of bladder cancer. We, therefore, evaluated whether flavopiridol inhibits growth and induces apoptosis in bladder cancer cells and additionally examined the toxicity and efficacy of this drug in vivo in a rat bladder cancer model. The in vitro experiments showed an IC20 of 50-100 nM in all cell lines tested. However, there was a difference in the response with regard to the grading of the tumor cells at higher doses. The IC50 was found to be 150-350 nM in the well-differentiated RT4 and RTI12 cell lines after treatment with flavopiridol, in comparison to a IC50 of 1000 nMfor the poorly-differentiated cell lines T24 and SUP. After exposure to flavopiridol, all tumor cell lines underwent significant apoptosis in comparison to untreated cells, beginning at a dose of 50 nM flavopiridol. At high concentrations (500 nM) of flavopiridol, 80-90% of all cells showed severe apoptotic alterations. The treatment of rat urinary bladder cancer with flavopiridol demonstrated the best efficacy with an intermittent treatment of 0.1 mg/kg, 3 times weekly over a total of 3 weeks, resulting in 7/12 animals tumor-free and a trend for the remaining tumors to have lower stage and grade. There seems to be a small advantage in intermittent versus daily application of flavopiridol. In summary, our results indicated that flavopiridol could be a useful therapeutic agent for bladder cancer, inhibiting tumor growth, malignant progression and inducing apoptosis.
机译:Flavopiridol是生物碱,罗希图金(一种来自印度树Dysoxylum binectariferum的化合物)的半合成黄酮类似物。已经显示出它抑制细胞周期蛋白依赖性激酶(CDK),从而引起细胞周期停滞和生长抑制。据报道,黄酮哌啶醇对多种癌细胞具有细胞毒活性,并已在多项临床试验中证明其功效。黄酮哌啶醇似乎是治疗膀胱癌的一种非常合适的潜在新药。因此,我们评估了黄酮哌啶醇是否抑制膀胱癌细胞的生长并诱导其凋亡,并另外在大鼠膀胱癌模型中检查了该药物的体内毒性和功效。体外实验显示,在所有测试的细胞系中IC20为50-100 nM。然而,在较高剂量下,关于肿瘤细胞分级的反应存在差异。发现黄素哌啶醇处理后,高分化RT4和RTI12细胞系的IC50为150-350 nM,而低分化细胞系T24和SUP的IC50为1000 nM。暴露于黄酮哌啶醇后,与未处理的细胞相比,所有肿瘤细胞系均经历了明显的凋亡,起始剂量为50 nM黄酮哌啶醇。在高浓度(500 nM)的黄酮哌啶醇中,所有细胞的80-90%显示出严重的凋亡变化。黄酮哌啶醇对大鼠膀胱癌的治疗表现出最佳疗效,以0.1 mg / kg的间歇性治疗,每周3次,共3周,导致7/12只动物无肿瘤,且其余肿瘤趋向于有较低的阶段和等级。黄酮哌啶醇的间歇给药与每日给药相比似乎有一个小的优势。总之,我们的结果表明黄酮哌啶醇可能是治疗膀胱癌,抑制肿瘤生长,恶性进展和诱导细胞凋亡的有用治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号